Sarcopenia Treatment Market Report
RA00024
Sarcopenia Treatment Market by Treatment Type (Protein Supplement, Vitamin D and Calcium Supplement, and Vitamin B 12 Supplement), and By Distribution Channel (Hospitals, Retail Channels, and Online Channels): Global Opportunity Analysis and Industry Forecast, 2019–2026
Update Available On-Demand
Sarcopenia Treatment Industry Outlook 2026:
The global Sarcopenia Treatment market size was valued at $ 2742.4 Million in 2018 and is projected to reach $ 3975.0 Million by 2026, registering a CAGR of 4.7% from 2018 to 2026. North America accounted for the highest share in 2018 and is anticipated to maintain its lead in the global Sarcopenia Treatment market throughout the forecast period.
Sarcopenia majorly affects older adults, mainly because ageing disables the ability to produce the proteins required by one’s body to maintain and grow muscles, resulting in functional disability due to decline of muscle structure. This in turn leads to premature mortality, disability as the patients are prone to fractures and worsened quality of life.
Thus, increasing geriatric population is expected to augment sarcopenia treatment market growth. For instance, According to the study published in IntechOpen Journal, 2017, the people aged 60 or over are expected to increase from 841 million to above 2 billion between 2013 and 2050. Thereby equating the geriatric population to 21.1% of the global population.
Moreover, sarcopenia enhances the risk of falls and fractures, as the elderly patients with sarcopenia have muscle loss, decreased strength and function. According to the various studies investigating the association of sarcopenia and falls, published in the Journal of Cachexia, Sarcopenia and Muscle, June 2019, higher risks of falls was reported among sarcopenic individuals compared with non?sarcopenic individuals.
According to the article published by the Conversation Media Group Ltd., sarcopenia affects an estimated 10-30 percent of older adults, varying by age and ethnicity. The condition affects higher percentage of around 40-50 percent for those aged over 80 and living in nursing homes, and up to 75 percent of the older adults in hospital settings. Furthermore, according to the study published in Springer Nature, 2017, the number of patients suffering from sarcopenia is expected to escalate from 10 million in 2016 to around 18 million in 2045, accounting to an overall increase of 72% in Europe.
Key players including GlaxoSmithKline plc, Radius Health Inc., Five Prime Therapeutics, Inc., Abbott Laboratories, Pfizer Inc., Sanofi S.A., Bayer AG, Novartis AG, Cadila Healthcare Ltd, Eli Lilly and Company, Nestlé S.A. and others holds major Sarcopenia Treatment market share.
Increasing research and development activities for development of novel therapies
Increasing investment in research and development to develop effective therapies is expected to augment sarcopenia treatment market growth.
For instance, in March 2018, BIOPHYTIS demonstrated results of Sarconeos (BIO101) for treating sarcopenia, and announced patient enrollment for the SARA-INT international clinical study, at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR).
In December, 2017, AMRA, a company offering body composition analysis services, and Artialis, specialists in musculoskeletal health, collaborated for conducting clinical trials for musculoskeletal disorders, thereby benefiting from AMRA’s technology. The aim of the collaboration is to identify more specific biomarkers for sarcopenia.
Increasing initiatives by government and private organizations
Various public and private organizations are actively involved in developing effective therapies for sarcopenia owing to lack of approved therapies, which is expected to propel market growth.
For instance, in 2016, the Aging in Motion (AIM) Coalition, held an annual meeting with the U.S. Food and Drug Administration (FDA) leaders, scientists, and industry experts to discuss research advances, advance clinical research and make available efficient treatment options for sarcopenia. AIM was initiated by the Alliance for Aging Research, in order to overcome obstacles that hinder the development and evaluation of promising treatments for sarcopenia.
Low awareness
Sarcopenia is a highly prevalent condition in the orthopedic patient population and correlates directly with higher falling rates, fractures, mortality and hospital costs. Lack of awareness in the geriatric population leading to poor disease diagnosis limits treatment adoption, thus hindering sarcopenia treatment market.
Also, sarcopenia is not as widely recognized as a geriatric syndrome compared to dementia or falls and is often not included into routine elderly care as therapies for treating the condition are still underway.
Absence of curative therapy
Currently, no approved muscle building agents for sarcopenia treatment are approved in the U.S., and non-drug therapies such as exercise, physical therapy, lifestyle and diet modification are the only primary methods for treating sarcopenia. Thus, the lack of effective therapies to treat the condition is a major factor creating a negative impact on the market growth.
Key Benefits for Sarcopenia Treatment Market:
-
This study presents the analytical depiction of the global Sarcopenia Treatment market analysis along with the current trends and future estimations to depict the imminent investment pockets.
-
The overall Sarcopenia Treatment market opportunity is determined by understanding the profitable trends to gain a stronger foothold.
-
The report presents information related to the key drivers, restraints, and opportunities of the global Sarcopenia Treatment market with a detailed impact analysis.
-
The current Sarcopenia Treatment market is quantitatively analyzed from 2018 to 2026 to benchmark the financial competency.
-
Porter’s five forces analysis illustrates the potency of the buyers and suppliers in the industry.
Sarcopenia Treatment Key Market Segments:
By Treatment Type
- Protein Supplement
- Vitamin D and Calcium Supplement
- Vitamin B 12 Supplement
By Distribution Channel
- Hospitals
- Retail Channels
- Online Channels
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- ASEAN
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
Research Objective and Assumption
-
Research Objectives
-
Assumptions
-
Abbreviations
-
-
Market Purview
-
Market Definition and Scope
-
Executive Summary
-
Market Snippet, By Drugs Type
-
Market Snippet, By Distribution Channel
-
Market Snippet, By Region
-
-
-
Market Dynamics, Regulations, and Trends Analysis
-
Market Dynamics
-
Drivers
-
Restraints
-
Market Opportunities
-
-
Impact Analysis
-
Disease Overview
-
Pipeline Analysis
-
Regulatory Scenario
-
Key Developments
-
PEST Analysis
-
Porter’s Analysis
-
-
Global Sarcopenia Treatment Market, By Treatment Type, (US$ Million)
-
Introduction
-
Market Share Analysis (%)
-
Y-o-Y Growth Analysis
-
Segment Trends
-
-
Protein Supplement
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
Vitamin D and Calcium Supplement
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
Vitamin B 12 Supplement
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
Others
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
-
Global Sarcopenia Treatment Market, By Distribution Channel (US$ Million)
-
Introduction
-
Market Share Analysis
-
Y-o-Y Growth Analysis
-
Segment Trends
-
-
Hospitals
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
Retail Channels
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
Online Channels
-
Introduction
-
Market Size and Forecast, and Y-o-Y Growth (US$ Million)
-
-
-
Global Sarcopenia Treatment Market, By Region (US$ Million)
-
Introduction
-
Market Share Analysis, By Region (%)
-
Y-o-Y Growth Analysis, For Regions
-
Regional Trends
-
-
North America
-
Market Size and Forecast, By Treatment Type (US$ Million)
-
Market Size and Forecast, By Distribution Channels (US$ Million)
-
Market Size and Forecast, By Country (US$ Million)
-
U.S.
-
Canada
-
-
-
Latin America
-
Market Size and Forecast, By Treatment Type (US$ Million)
-
Market Size and Forecast, By Distribution Channels (US$ Million)
-
Market Size and Forecast, By Country (US$ Million)
-
Brazil
-
Mexico
-
Argentina
-
Rest of Latin America
-
-
-
Europe
-
Market Size and Forecast, By Treatment Type (US$ Million)
-
Market Size and Forecast, By Distribution Channels (US$ Million)
-
Market Size and Forecast, By Country (US$ Million)
-
Germany
-
U.K.
-
France
-
Italy
-
Spain
-
Russia
-
Rest of Europe
-
-
-
Asia Pacific
-
Market Size and Forecast, By Treatment Type (US$ Million)
-
Market Size and Forecast, By Distribution Channels (US$ Million)
-
Market Size and Forecast, By Country (US$ Million)
-
China
-
India
-
Japan
-
Australia
-
South Korea
-
ASEAN
-
Rest of Asia Pacific
-
-
-
Middle East
-
Market Size and Forecast, By Treatment Type (US$ Million)
-
Market Size and Forecast, By Distribution Channels (US$ Million)
-
Market Size and Forecast, By Country (US$ Million)
-
GCC
-
Israel
-
Rest of Middle East
-
-
-
Africa
-
Market Size and Forecast, By Drugs Type (US$ Million)
-
Market Size and Forecast, By Distribution Channels (US$ Million)
-
Market Size and Forecast, By Country, (US$ Million)
-
South Africa
-
Central Africa
-
North Africa
-
-
-
-
Competitive Landscape
-
Company Profiles
-
GlaxoSmithKline plc*
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Radius Health Inc.
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Five Prime Therapeutics, Inc.
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Abbott Laboratories
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Pfizer Inc.
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Sanofi S.A.
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Bayer AG
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Novartis AG
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Cadila Healthcare Ltd
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Eli Lilly and Company
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
Nestlé S.A.
-
Company Overview
-
Product Portfolio
-
Key Highlights
-
Financial Overview
-
Market Strategy
-
-
-
Sarcopenia is defined as age-related loss of muscle mass and is a key physiological component of frailty. Moreover, sarcopenia is associated with increased risk for several adverse health outcomes such as frailty, disability, falls and mortality. The major mechanisms leading to sarcopenia include age-related decline in α-motor neurons, IGF-1, and DHEA-S and increase in catabolic cytokines (IL-6). The condition is also characterized by a significant decrease in skeletal muscle protein synthesis and increase in protein breakdown. Age related sarcopenia is considered primary, while sarcopenia is considered secondary when factors other than ageing such as disease and nutrition are evident.
Factors such as rising prevalence of sarcopenia with increasing geriatric population, increasing research and development activities for development of novel therapies and increasing initiatives by government and private organizations are anticipated to boost the growth of the market. However, low awareness and absence of curative therapy is expected to hinder the growth of sarcopenia market.
Among the analyzed regions, currently, North America is the highest revenue contributor, and is expected to maintain the lead during the forecast period, followed by Europe, Asia Pacific, Latin America, Middle East and Africa.
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
